Query our full-text historical index across market dispatches, earnings reports, central bank policies, and financial analyses.
Moderna Chief Executive Stéphane Bancel remains steadfast on the company's individualized cancer vaccine program despite recent equity selloffs and shifting market expectations.
GSK shares fell sharply after disappointing vaccine sales raised investor concerns over slowing demand for flagship treatments and intensifying sector competition.
Moderna shareholders face prolonged market turbulence as the biotech pioneer balances falling COVID-19 vaccine revenues with heavy R&D bets across oncology and rare diseases.